Basic information
- Name:
1H-Benzimidazole,6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-
- Superlist Name:
- Pantoprazole
- CAS No.:
102625-70-7
- Molecular Structure:
![Molecular Structure of 102625-70-7 (1H-Benzimidazole,6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-)](http://www.lookchem.com/300w/2010/0612/102625-70-7.jpg)
- Formula:
- C16H15F2N3O4S
- Molecular Weight:
- 383.37
- Synonyms:
- 1H-Benzimidazole,5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- (9CI);2-[[(3,4-Dimethoxypyridin-2-yl)methyl]sulfinyl]-5-difluoromethoxy-1H-benzimidazole;5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole;5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole;BY 1023;Pantozol;SKF 96022;
- Density:
- 1.51 g/cm3
- Boiling Point:
- 586.9 °C at 760 mmHg
- Flash Point:
- 308.7 °C
- Appearance:
- almost white solid
- Hazard Symbols:
Xn- Risk Codes:
- 20/21/22-37/38-41-48
- Safety Description:
- 22-26-36/37/39-45 Details
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Specification
The IUPAC name of 1H-Benzimidazole,6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]- is 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H-benzimidazole. With the CAS registry number 102625-70-7, it is also named as Pantoprazole. The product's categories are Active Pharmaceutical Ingredients; APIs; Pantoprazole. It is almost white solid.
The other characteristics of this product can be summarized as: (1)ACD/LogP: 1.69; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.68; (4)ACD/LogD (pH 7.4): 1.59; (5)ACD/BCF (pH 5.5): 11.13; (6)ACD/BCF (pH 7.4): 9.09; (7)ACD/KOC (pH 5.5): 194.55; (8)ACD/KOC (pH 7.4): 158.88; (9)#H bond acceptors: 7; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 7; (12)Polar Surface Area: 94.68 Å2; (13)Index of Refraction: 1.642; (14)Molar Refractivity: 91.35 cm3; (15)Molar Volume: 252.7 cm3; (16)Surface Tension: 73.4 dyne/cm; (17)Enthalpy of Vaporization: 87.64 kJ/mol; (18)Vapour Pressure: 9.37E-14 mmHg at 25°C; (19)Rotatable Bond Count: 7; (20)Tautomer Count: 2; (21)Exact Mass: 383.075133; (22)MonoIsotopic Mass: 383.075133; (23)Topological Polar Surface Area: 106; (24)Heavy Atom Count: 26; (25)Complexity: 490.
Preparation of 1H-Benzimidazole,6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-: The condensation of 5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole (I) and 2-(Chloromethyl)-3,4-dimethoxypyridinium hydrochloride gives compound (Ⅲ). Then, after oxidation with m-chloroperbenzoic acid, we can get the product.
.gif)
.gif)

Uses of 1H-Benzimidazole,6-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-: It is a proton pump inhibitor drug that inhibits gastric acid secretion. It is also used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
When you are using this chemical, please be cautious about it as the following:
It is not only harmful by inhalation, in contact with skin and if swallowed, but also irritating to respiratory system and skin. And it has danger of serious damage to health by prolonged exposure. So people should not breathe dust. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. If you want to contact this product, you must wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
People can use the following data to convert to the molecule structure.
1. SMILES:FC(F)Oc3cc1c(nc(n1)S(=O)Cc2nccc(OC)c2OC)cc3
2. InChI:InChI=1/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
The following are the toxicity data which has been tested.
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | oral | 3mg/kg/5D-I (3mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS LIVER: OTHER CHANGES | Australian and New Zealand Journal of Medicine. Vol. 29, Pg. 833, 1999. |

